Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models by Rico, María José et al.
Oncotarget2874www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/                    Oncotarget, 2017, Vol. 8, (No. 2), pp: 2874-2889
Metformin and propranolol combination prevents cancer 
progression and metastasis in different breast cancer models
María Rico1,2,*, María Baglioni1,*, Maryna Bondarenko3, Nahuel Cesatti Laluce1, 
Viviana Rozados1, Nicolas André3,4,5, Manon Carré3, O. Graciela Scharovsky1,2,5, 
Mauricio Menacho Márquez1,2
1Instituto de Genética Experimental, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina
2El Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina
3Aix-Marseille Université, Inserm UMR_S 911, Centre de Recherche en Oncologie biologique et Oncopharmacologie, Faculté 
de Pharmacie, Marseille, France
4Service d'Hématologie and Oncologie Pédiatrique, AP-HM, Boulevard Jan Moullin, Marseille, France
5Metronomics Global Health Initiative, Marseille, France
*These authors contributed equally and are co-first authors
Correspondence to: M Menacho-Márquez, email: mmenacho@conicet.gov.ar 
Keywords:  breast cancer, metronomics, drug repositioning, metformin, propranolol
Received: July 22, 2016    Accepted: November 22, 2016    Published: December 01, 2016
ABSTRACT
Discovery of new drugs for cancer treatment is an expensive and time-consuming 
process and the percentage of drugs reaching the clinic remains quite low.
Drug repositioning refers to the identification and development of new uses for 
existing drugs and represents an alternative drug development strategy. 
In this work, we evaluated the antitumor effect of metronomic treatment with a 
combination of two repositioned drugs, metformin and propranolol, in triple negative 
breast cancer models.
By in vitro studies with five different breast cancer derived cells, we observed 
that combined treatment decreased proliferation (P < 0.001), mitochondrial activity 
(P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in 
immunocompetent mice confirmed the potential of this combination in reducing tumor 
growth (P < 0.001) and preventing metastasis (P < 0.05). 
Taken together our results suggest that metformin plus propranolol combined 
treatment might be beneficial for triple negative breast cancer control, with no 
symptoms of toxicity. 
INTRODUCTION
Among breast cancer subtypes, triple-negative 
breast cancer (TNBC) exhibit characteristics distinct from 
the others, as they are particularly aggressive, frequently 
recur and become metastatic. TNBC accounts for 15% 
of all breast cancer types with higher percentages in 
premenopausal African-American and Hispanic women, 
and it is associated with very poor prognosis and limited 
treatment options availability [1].
Drug repositioning refers to the assignation of new 
uses for existing drugs and represents an alternative drug 
development strategy. In oncology there is an increasing 
interest in the use of non-cancer drugs for cancer treatments 
due to the previous detailed knowledge of pharmacokinetics/
dynamics and toxicities, and because most repositioned 
drugs are available at low cost, normally as generics [2] 
which provides an opportunity to bypass partially the early 
costs and time associated to new drugs development. This 
is a particular issue for low-income countries, where the 
availability of drugs for cancer treatment is very limited and 
restricted to some essential cytotoxic drugs and cost is a 
major factor in influencing access to cancer therapies [3].
Drug repositioning is frequently combined with 
metronomic chemotherapy to what has been defined as 
“metronomics” [3]. Metronomic chemotherapy refers to 
the regular administration of conventional chemotherapy 
drugs at low, minimally toxic doses, without long resting 
periods of time [4]. Importantly, several phase II trials 
have shown effectiveness of metronomic therapies on 
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different cancer types including TNBC with different 
drugs [5]. Interestingly, developed and approved drugs 
that showed an anti-cancer opportunity for therapy can 
be administered orally, on daily basis, in a metronomic 
fashion.
The anti-diabetic metformin (Met) has been shown 
to have anticancer properties involving both direct 
(insulin-independent) and indirect (insulin-dependent) 
actions. Retrospective studies have reported that patients 
with diabetes receiving Met exhibited decreased cancer 
incidence and cancer-related mortality [6–8]. These 
studies were complemented with a growth-inhibitory 
effect observed for Met on breast cancer cells in culture 
and a reduction on mammary tumor growth in mice 
[9, 10] and a synergistic action of Met with EGFR 
inhibitors [11, 12]. Interestingly, Met was also found to be 
effective against tumors expressing constitutively active 
phosphatidylinositol-3 kinase [PI3K; 13] and trastuzumab-
refractory breast cancer xenografts [14]. Also, preliminary 
results from clinical trials showed that Met administration 
have an impact on tumor proliferation markers [15]. 
The indirect anticancer effect of Met involves 
insulin dependent actions, associated with a reduction 
of insulin circulating levels that lead to a decrease in 
the mitogenic and antiapoptotic potential of insulin. In 
this way, Met may diminish the pro-stimulatory effect 
of insulin on cancer cells. Met direct effects are linked 
to inhibition of mitochondrial complex I [16]. This 
inhibition interrupts mitochondrial respiration, decreasing 
proton-driven synthesis of ATP, causing cellular energetic 
stress and elevation of the AMP:ATP ratio which, in turn, 
activates AMP-activated protein kinase (AMPK), a key 
cellular energy sensor kinase [10]. AMPK activation leads 
to a reduction in mammalian target of rapamycin (mTOR) 
signaling, protein synthesis and proliferation [16–18].
Propranolol (Prop) is a noncardioselective 
β-adrenergic receptor blocker with reported antioxidant 
and anti-inflammatory properties, used traditionally for 
hypertension, angina pectoris, myocardial infarction, 
migraines, anxiety disorders, and tremor [19]. It was 
previously shown that Prop reduces intracellular calcium 
levels, Bax-mediated cytochrome C release and inhibits 
protein kinase C (PKC) activity in a β-adrenoreceptor 
independent manner [19–21], and it induces cell cycle 
arrest and apoptosis via Akt/MAPK pathway in melanoma 
cells [22]. Many studies in humans have demonstrated 
its efficacy for the treatment of infantile haemangioma. 
In this regard, it seems that Prop exerts its suppressive 
effects acting through the HIF-1α-VEGF-A angiogenesis 
axis, with effects mediated through the PI3K/Akt and 
p38/MAPK pathways [23]. In relation to breast cancer, 
retrospective studies reported an improved survival with 
reduction in the risk of recurrence in woman receiving this 
β-blocker therapy [24].
In this study we evaluated the effect of metronomic 
combined administration of two repositioned drugs, Met 
and Prop, on different models of TNBC both in vitro 
and in vivo. We found that combined treatment was 
effective on preventing cell growth, triggering apoptosis 
and decreasing migratory/invasive capabilities of cells 
in vitro, probably through their action on mitochondrial 
bioenergetics. In a similar way, combined treatment 
was able to reduce tumor growth in vivo, preventing 
development of lung metastasis and increasing mice 
survival, without symptoms of toxicity. These results 
unveil a new combinatorial low-cost treatment with no 
signs of toxicity for a type of tumors that normally have 
limited treatment options paving the way for genuine 
global oncology.
RESULTS
Met and Prop act synergically on breast tumor 
cell lines viability
We first analyzed the effect of treatment with Met 
and Prop on the growth of 5 different breast tumor-
derived cells. Both drugs were able to reduce cell 
growth in a dose dependent manner (Figure 1A, 1B and 
Supplementary Figure S1A, S1B) at different levels 
in all the cells tested, as seen by colorimetric assays. 
Noteworthy, combined treatment with Met + Prop 
showed a stronger effect on cell growth that single agent 
treatment (Figure 1C and Supplementary Figure S1C). 
Interestingly, nor single or combined treatments caused 
significant effects on non-tumoral cell line MDCK 
(Supplementary Figure S1A–S1C). Dynamic monitoring 
of cell proliferation using impedance technology 
strengthened these observations. 4T1 cells growth 
kinetics was slowed down by Met or Prop individual 
treatment compared to vehicle-treated cells (Figure 1D). 
Indeed, cell-doubling time determined before cell 
confluence, was significantly (Met: P < 0.05; Prop: 
P < 0.01) increased by those treatments (Figure 1E). 
More importantly, combination of Met and Prop was 
significantly more potent to reduce ability of 4T1 cells 
to divide, showed by growth kinetics and doubling time 
calculation (Figure 1D, 1E; Supplementary Figure S1D). 
Drug cytostatic effects were further highlighted by 4T1 
cell population stabilization from 16 h after starting 
treatment (i.e. 40–88 h; Figure 1D). Combining Met 
with Prop led to greater activity as shown by reductions 
in slope values (Supplementary Figure S1E). Impedance 
measurements in MDA-MB-231 cells confirmed that 
combination of Met and Prop was effective leading to 
a decrease in both growth kinetics and doubling time 
(Figure 1F, 1G). Indeed, the combination was found 
to act synergically on 4T1 and MDA-MB-231 cells, as 
demonstrated by calculation of IC50 for each drug in the 
presence of the other (Supplementary Figure S1F, S1G). 
As Met and Prop administration to patients is 
usually carried out on a “metronomic” manner, we decided 
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Figure 1: Met and Prop effect on breast tumor cells viability. Cells were cultured in the presence of the indicated doses of Met 
(A) or Prop (B) during 24 hours. The number of metabolically active cells was estimated by tetrazolium salts reduction method (n = 3). 
(C) 4T1 (left panel), MDA-MB-231 (middle panel) and M-406-derived cells (right panel) were treated for 24 hours with Met (M; 1 mM), 
Prop (P; 1 µM) or a combination of them (M+P) and living cells were estimated as before (n = 3). (D–G) Cell proliferation and doubling 
time evaluation by real time impedance-based method for 4T1 (D, E) and MDA-MB-231 (F, G). Arrows indicate the moment of treatment 
addition (Met 1 mM, Prop 10 µM).
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to explore if the continuous exposure to these drugs could 
lead to stronger effects on cell proliferation. We compared 
the impact on proliferation of short-term treatment 
(approximately equivalent to a cell doubling time) and a 
continuous 144 hours metronomic treatment. Calculations 
of IC50 in these two conditions revealed that treatment with 
Met and Prop in a metronomic basis increased drastically 
(as example, Met IC50 values for 4T1 cells: from 5.8664 to 
0.1656) cells sensitivity to these two repositioned drugs 
(Table 1).   
Treatment with Met and Prop also affected the 
ability of 4T1 (Figure 2A, 2B and Supplementary 
Figure S2A) and MDA-MB-231 (Supplementary 
Figure S2B) cells to form colonies, altering the number of 
viable clones (Met+Prop, P < 0.001) and their size (Met 
+ Prop, P < 0.001). 
To further characterize the effect of Met and Prop 
on viability, we evaluated the induction of apoptosis by 
treatments. Both, Met and Prop increased significantly the 
number of 4T1 and MCF7 apoptotic cells (Figure 2C, 2D 
and Supplementary Figure S2C). Prop induced apoptosis 
in MDA-MB-231 and M-234p-derived cells. In a similar 
manner, Met alone promoted increase in apoptotic 
population of M-406-derived cells (Supplementary 
Figure S2C). Nevertheless, regardless the cell type or the 
individual treatment effect, combination of drugs triggered 
apoptotic response in all the cells tested, in significant 
higher levels than any individual treatment (Figure 2C, 
2D and Supplementary Figure S2C). 
Combining Met to Prop leads to a strong 
inhibition of mitochondrial bioenergetics
To assess the effect of treatment on mitochondrial 
respiration in intact 4T1 cells, we performed real-
time measurements of the oxygen consumption rate 
Figure 2: Met and Prop affect the clonogenic behaviour and trigger apoptosis in breast cancer cells. Cells (500 cells/well) 
were cultured in the presence of Met (5 mM) and/or Prop (5 µM) during 8 days. Colonies were visualized by Giemsa staining (A) in order to 
allow quantification (B, top panel). Clones photos were taken at different times (A, lower panel) and their size was estimated by measuring 
colonies diameters with the Image J software (B, bottom panel). (C, D) Analysis of the degree of apoptosis triggered by Met (5 mM) and/
or Prop (5 µM): After 24 hours of treatment with the indicated drugs, 4T1 cells were collected, washed and stained with Annexin V-FITC 
and Propidium Iiodide. The percentage of apoptotic populations was analyzed by flow cytometry. (C) Flow cytomety profiles for 4T1 cells. 
(D) Quantification of the percentage of Annexin V+ apoptotic cells. (M: Met, P: Prop, M+P: Met+Prop; n = 3).
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(OCR). After a 4 h-incubation with Prop, cells showed 
a basal respiration and a mitochondria-governed ATP 
generation reduced by 35% and 33%, respectively, as 
compared to control (Figure 3A, 3B). Met also induced a 
noticeable dose-dependent decrease in both mitochondrial 
respiration and ATP production, which reached -77% and 
-83% respectively at 7.5 mM (Figure 3A, 3B). These 
mitochondrial activities were completely abolished at 
24 h, even with the lowest concentration of Met (-93% 
respiration at 1 mM; Figure 3C). Importantly, the 
mitochondrial inhibitory functions of Met were increased 
by Prop (Figure 3A–3C). This was especially the case 
for the lowest concentration of Met that, when combined 
to Prop, further significantly reduced basal respiration 
by 71% (Figure 3A) and respiration-linked ATP by 69% 
(Figure 3B). When electron transport chain uncoupler 
FCCP was added, mitochondrial respiration was stimulated 
mimicking an increase in energy demand and showing the 
maximal respiration rate (Figure 3D). In this case, the 
combination between small doses of Met with Prop was 
still more active than the two drugs alone to reduce 4T1 
cells oxygen consumption rate (OCR). In line with this, the 
spare capacity –defined as the difference between maximal 
and basal respiration– was also significantly diminished 
by the combinatorial treatment (P < 0.01; Figure 3E). 
These results definitely demonstrated the potent anti-
mitochondrial properties of the Prop/Met combination, 
even at low concentrations.
Met and Prop combination drastically activates 
glycolysis
Cancer cells are known for their ability to shift 
their metabolic phenotype. Taking into account the 
inhibition of the mitochondrial oxidative phosphorylation 
by Prop and Met, we then determined whether 4T1 
cells in turn hyper-activated glycolysis. We therefore 
measured the extracellular acidification rate (ECAR) 
that reflects lactate release over time. In this context, 
we found that cells exposed to different doses of Met 
for 4 h showed a dose-dependent increase in ECAR, 
after glucose addition (Figure 3F). Prop treatment also 
stimulated basal glycolysis, in a time-dependent manner 
(Figure 3G). While its effect was limited after 4 h when 
used alone, Prop significantly enhanced the pro-glycolysis 
properties of Met, especially for the lowest concentrations 
(Figure 3H). Following addition of the ATP synthase 
inhibitor oligomycin, cells treated with either vehicle, Prop 
alone or Met alone exhibited higher ECAR (Figure 3H). 
In contrast, the Met/Prop combinations –whatever 
the concentrations used– forced 4T1 cells to activate 
glycolysis up to the maximum extent, as revealed by their 
insensitivity to oligomycin. Lastly, we represented 4T1 
cell energy phenotype that comprises a baseline phenotype 
(starting medium condition), a stressed phenotype 
(mediated by FCCP for OCR and by oligomycin for 
ECAR), and a metabolic potential (Figure 3I). This 
last parameter reveals the cells’ ability, and preferred 
energetic pathway, to respond to supplemental energy 
demand due to stress. It confirmed that, when exposed to 
the combinatorial treatment, 4T1 cells energy phenotype 
dramatically changed, due to both treatment inhibitory 
properties of mitochondria oxidative phosphorylation and 
cells incapacity to further mobilize the glycolytic pathway. 
Met and Prop affect metastasis related events  
in vitro
In order to characterize properties of the cells related 
to metastatic processes, we explored breast cancer cell 
migration and invasion abilities in the presence of Met 
and/or Prop. Both drugs significantly reduced (P < 0.01) 
the migratory properties of 4T1 and MDA-MB-231 cells 
in an in vitro wound-healing assay (Figure 4A–4E). In 
addition, both drugs reduced the invasion efficiency of 
4T1 and MDA-MB-231 cells in a conventional assay 
with matrigel, but only metformin did it significantly 
(P < 0.01) for human cells (Figure 4F–4H). Furthermore, 
as previously shown for growth and apoptosis, combined 
treatment exacerbated migratory and invasive defects 
triggered by treatments in both cell lines (Figure 4A–4F, 
Supplementary Figure S3).
Combined treatment with Met and Prop reduces 
in vivo breast tumor growth affecting positively 
mice survival
To confirm our in vitro findings, we examined the 
effect of metronomic treatment with the drugs in two 
models of TNBC: 4T1 and M-406. Drug dosage was based 
on literature data and was associated with no toxicity. The 
choice was based in articles using Met or Prop to treat 
Table 1: IC50 values of metformin and propranolol on 4T1, MDA-MB-231 and MCF7 cells treated 
for 36 h or 144 h
Cell type
Short term treatment Metronomic treatment
IC50 Met (mM) SEM IC50 Prop (µM) SEM IC50 Met (mM) SEM IC50 Prop (µM) SEM
4T1 5.8664 0.2318 5.2007 0.4317 0.1656 0.0079 0.1042 0.0154
MDA-MB-231 5.9028 0.3928 7.9109 0.2006 0.2742 0.0112 0.2148 0.0091
MCF7 1.0799 0.0701 7.9716 0.1954 0.0709 0.0283 0.1788 0.0262
Results are expressed as mean ± SEM. In all the cases for each drug and cell type, IC50 (short term treatment) vs IC50 (metronomic treatment) P < 0.001.
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Figure 3: Combination of Met and Prop shows anti-mitochondrial properties and stimulates glycolysis. 4T1 cells treated 
with Prop (10 µM) and Met (1, 3.75 and 7.5 mM) alone or in combination for 4 h were analyzed for mitochondrial bioenergetics using 
the Seahorse XF technology. Measurement of basal level of oxygen consumption rate (OCR) was followed by sequential injections of 
FCCP and rotenone/antimycin A to allow determination of the amount of non-ATP-linked oxygen consumption (proton leak), the maximal 
respiration and the non-mitochondrial oxygen consumption. (A) Basal respiration, calculated as the difference between basal OCR and non-
mitochondrial OCR. (B) ATP-linked OCR, defined as the difference between basal OCR and non-ATP-linked oxygen consumption. (C) 
Basal respiration of 4T1 cells exposed to Met and Prop for 24 h. (D) Real-time mitochondrial bioenergetic profile of live 4T1 cells after a 
4 h-treatment with Prop 10 µM, Met 1 mM, and the combination. (E) Spare capacity, defined as the difference between basal and maximal 
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diabetes and hypertension respectively [25, 26]. Mice 
treated with Met and/or Prop developed tumors which 
showed a significant slower growth kinetics, as measured 
by the decreased tumor volume when compared to the 
control and the increased tumor doubling time (Figure 5A, 
5C and Supplementary Figure S4A, S4B). This 
decrease in tumor growth also correlated with reduced 
proliferation associated with treatments (P < 0.001), as 
seen by immunostaining with Ki67 proliferation marker 
(Figure 5E, 5F). The combined treatment was more 
efficient in slowing down tumor growth (4T1: P < 0.05 
from day 15; M-406: P < 0.05 from day 20; Figure 5A, 5C 
and Supplementary Figure S4A, S4B), which is related to a 
significant increase in apoptosis (P < 0.05; Figure 5G, 5H). 
Combined treatment was also associated with a 
significantly (P < 0.001) improved survival of mice 
bearing both 4T1 and M-406 tumors (Figure 5B, 5D). 
Interestingly, there were no signs of toxicity associated 
with treatments as seen by analysis of mice weight 
evolution (Supplementary Figure S4C, S4D) and general 
behavior (data not shown).
Combination of Met and Prop reduces 
metastasis development
The examination of tumor-bearing animals, at the 
end of the tumorigenesis assays, indicated that the number 
of metastasis of M-406 cells to the lungs was significantly 
decreased (P < 0.05) upon treatment with Met and Prop 
(Figure 6A, 6B; Table 2). Nevertheless, there were no 
significant differences in metastasis number at the end of 
the experiment for 4T1 cells (Supplementary Figure S4E). 
To further widen the analysis of the effect of 
treatments on lung colonization properties by breast cancer 
cells, we introduced M-406 or 4T1 cells intravenously 
in recipient mice. Consistent with our previous finding, 
we observed that breast cancer cells had impaired lung 
colonization ability when mice were under combined 
treatment (Figure 6C–6F), suggesting that treatments 
are, at least, affecting post-intravasation steps during 
metastasis process. Indeed, inspection of metastasis 
evinced a reduced size for metastatic nodules when mice 
were treated with Prop, either alone or in combination 
with Met (Figure 6G, 6H), suggesting also an effect of 
this β-blocker on the ability of cells to grow on lung 
epithelium. 
DISCUSSION
TNBC represent from 10 to 20% of breast cancer 
and is usually associated with poor prognosis and limited 
treatment options [27]. Cancer therapies currently applied 
cause significant side effects negatively impacting the 
patient’s quality of life [28, 29]. Hence, there is an urgent 
need to develop clinically effective and well-tolerated new 
therapeutic approaches. 
Met and Prop are being currently used to treat 
diabetes and cardiovascular illnesses, both conditions 
known as age-related diseases. Common cancer is also 
considered an aging-related condition, so the use of anti-
aging repurposing drugs could be helpful to prevent or 
treat cancer [30–32]. During the last decade Met has been 
associated with a reduced incidence and severity of several 
types of cancer, and retrospective studies suggested a benefit 
of using ß-blockers for breast cancer patients [6–8; 33].
We report here that a combination of two 
repositioned drugs, namely Met and Prop, was able to slow 
down the growth of all the triple negative tumor cell lines 
and tumor-derived cells tested. They also were effective on 
the estrogen receptor (ER) positive MCF7 cells. Indeed, in 
all the cell types analyzed and regardless the method used, 
combination of Met+Prop showed a significantly stronger 
effect on cell growth than any individual drug. In fact, our 
in vitro data with 4T1 and MDA-MB-231 cells revealed 
that Met and Prop worked together in a synergistic 
manner blocking proliferation as it can be easily seen by 
the position of IC50 values falling below the additivity 
curve. Interestingly, the combination of these two drugs 
was effective not only to inhibit proliferation, but also 
to diminish the clonogenic capability and to increase 
apoptosis of the tumor cells.
In order to somehow mimic the metronomic 
administration of drugs under study, we performed 
proliferation assays in continuous presence of Met or 
Prop. It was evident that constant administration of 
low doses of Met and Prop had a stronger effect on cell 
proliferation than a short-term exposure, as seen by the 
drastic decrease (around 20 times for Met and 40 times for 
Prop) on IC50 value for these drugs when metronomically 
administered. This is not a special feature of these two 
drugs, but rather a consequence of the administration 
schedule. Indeed a stronger effect of topotecan and 
pazopanib was also recently described when supplied 
rates. (F) Real-time measure of extracellular acidification rate (ECAR) was performed in intact 4T1 cell cultures first incubated in assay 
medium without glucose and pyruvate, and then successively supplemented with glucose, with the ATP synthase inhibitor oligomycin that 
consequently accelerate the glycolytic process, and with the glycolysis inhibitor 2-deoxy-glucose (2-DG). (G) Basal glycolysis, calculated 
as the difference between glucose-mediated ECAR and rates without glucose, in 4T1 cells treated with vehicle or Prop 10 µM for the 
indicated times. (H) Basal and oligomycin-stimulated ECAR in cells incubated for 4 h with a range of concentrations of drugs alone or 
combined. (I) Energy phenotype of 4T1 cells after a 4 h-treatment with Prop and/or Met. Mitochondrial respiration and glycolysis were 
first simultaneously analyzed under the starting medium conditions (Baseline Phenotype) and then upon injection of FCCP and oligomycin, 
respectively (Stressed Phenotype). The metabolic potential (dotted lines) revealed 4T1 cells ability to meet an energy demand, and preferred 
pathway. (M: Met, P: Prop, M + P: Met + Prop; n = 3).
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metronomically in breast cancer preclinical models [34]. 
To date, there is not clear correlation between in vitro Met 
effective antitumoral doses and the concentration of this 
drug observed in patient’s plasma [35, 36]. Nevertheless, 
our observation of increased effectiveness (i.e. decrease 
on IC50 values) for both Met and Prop when administrated 
metronomically, together with their synergistic action, 
allow us to speculate that metronomic administration of 
this combined treatment could be effective at levels of Met 
as low as the ones found in patient’s plasma. 
Importantly, results from our in vivo experiments 
in TNBC models corroborate the in vitro efficacy of the 
combination. Animals receiving combined treatment 
were indeed those with a slower tumor growth, for both 
M-406 and 4T1 tumors. Moreover, Met+Prop treatment 
improved survival of tumor bearing mice, which also 
showed no signs of toxicity. This combinatorial treatment 
thus endows with two important features: effectiveness 
and lack of toxicity. Our data are in agreement with 
a recent publication that reported the effectiveness of 
combining Met and β-blocker atenolol in a mouse tumor 
model [37]. Nevertheless, it is worthwhile mentioning 
that the antitumor effect was achieved with atenolol doses 
that were quite higher than those of Prop used herein. 
This could be due to the action of propranolol on beta-
2 adrenergic receptors (ADRB2). Interestingly, it was 
recently reported that Prop inhibits glucose metabolism 
of breast cancer cells through ADRB2-dependent 
Figure 4: Met and Prop affect metastatic-related events in vitro. Wound healing assay was performed as described in Materials and 
Methods. Cellular motility was estimated by measuring closure of the initial wound. Photos were taken at the indicated times (A, 4T1 cells). 
Quantification of healing was performed using the Image J software and the area under the curve (A.U.C.) was calculated (B, C; 4T1 cells; 
D, E: MDA-MB-231 cells; n = 3). (F–G) Cells were seeded onto matrigel-coated transwells and incubated in presence or absence of drugs. 
Invading cells were stained with Giemsa (F). Quantification of invading cells was performed for 4T1 (G) and MDA-MB-231 (H) cells. 
Met 5 mM; Prop 5 µM.
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posttranscriptional downregulation of hexokinase-2 [38]. 
It is also important to note that Prop is able to inhibit 
M2 macrophages polarization, triggered by activation of 
ADRB2 [39], an issue that could account for the reduced 
tumor growth in immunocompetent mice which, however, 
needs to be explored in more detail.
The antineoplastic activity of Met has attracted 
the attention of many researchers. It has been found that 
Figure 5: Tumor growth delay and improved survival of animals treated with Met and Prop. Immunocompetent mice were 
orthotopically challenged with 4T1 cells (A, B) or M-406 tumor inolucum (C–H). Three days later Met (2g/l), Prop (25 mg/l) or both were 
added to the drinking water. The tumor size was measured biweekly with a calliper (A, C; P < 0.05 since the day indicated between square 
brackets). Survival was estimated for each group and data were statistically analyzed by long-rank Mantel-Cox test (B, D, P < 0.001). 
During exponential growth, tumors were collected and histological sections stained (E) and quantified (F) for Ki67 proliferative marker, or 
stained (G) and quantified (H) to determine apoptosis by TUNEL assay (scale bar = 50 µm).
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Met triggers cell cycle arrest at the G1 phase and induces 
apoptosis in a wide panel of breast cancer cell lines [40]. 
These effects are likely to be related to AMPK activation, 
enzyme that senses redox and metabolic imbalance [41]. 
Conversely to what was initially hypothesized by Warburg, 
it is now widely accepted that mitochondria are functional 
in a large majority of tumors [42]. The discovery that 
Met inhibits mitochondrial complex 1 activity in cancer 
cells opened new horizons for biguanides in the field of 
cancer metabolism. The mitochondrial effect is confirmed 
in our study by OCR abolition in breast cancer 4T1 cells 
and, consequently, by a severe reduction in mitochondria-
driven ATP synthesis.
On the other hand, we showed here the anti-
proliferative properties of Prop in various breast cancer 
cells, in agreement with our previous results in breast 
carcinoma in vitro and in vivo models [43]. We contributed 
to highlight the drug deleterious effects on mitochondrial 
network functions and dynamics in various cancer cells 
[44, 45], but Prop mechanism of action remained non-
elucidated in breast cancer cells. Here, we showed that 
Prop induces apoptosis in various breast cancer cell lines. 
Moreover, we revealed that it disrupts bioenergetics 
in intact cells, and especially through the inhibition of 
respiration and ATP generation by mitochondria. Our 
results are consistent with a very recent study showing that 
atenolol inhibits the respiratory chain complex I in MDA-
MB-436 and ZR-75-1 breast cancer cells [37].
We further showed the efficacy of combining Prop 
to low doses of Met to achieve a complete suppression 
of the mitochondrial bioenergetics. Prop may thus 
enhance the Met-mediated inhibition of mitochondrial-
dependent metabolic intermediates required for cell 
growth and survival [16, 46]. Consistently, complete 
abolition of mitochondrial respiratory activity has been 
shown to prevent tumorigenesis in murine breast cancer 
models [47] and to inhibit the in vivo growth of human 
breast cancer cells [48]. The drop in mitochondrial 
oxidative phosphorylation rate in cells exposed to the 
Met+Prop combination led, in turn, to a noticeable 
increase in glycolysis. The metabolic reprogramming 
from mitochondrial respiration to aerobic glycolysis is 
generally described to support cancer cell proliferation and 
tumor growth [49]. Nevertheless, previous studies have 
demonstrated that Met can slow down cancer cell division 
in presence of abundant amounts of glucose and induce 
Figure 6: Combination of Met and Prop prevent development of metastasis. Lungs from mice carrying M-406 tumors were 
observed at the time of death to determine the presence of spontaneous metastasis (A, B). Mice were i.v. injected with 4T1 cells (C) or 
M-406-derived cells (D). Fifteen days after injection lungs were stained with ink to allow metastasis quantification. Data are shown in a 
box and whisker plot and represented as median, first and third quartiles, and maximum and minimum of all data (E: 4T1 cells; F: M-406-
derived cells). Metastatic nodes diameters were measured with a calliper (G: 4T1 cells; H: M-406-derived cells; C: control; M: Met (2 g/l); 
P:Prop (25 mg/l); M+P: Met+Prop; n = 7). 
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cancer cell death in deprived glucose conditions [16, 50]. 
By enhancing glycolysis to an extraordinarily high rate, 
the Met + Prop combination probably leads to glucose 
deprivation in tumor cell microenvironment. Combining 
these two stress-energy mimickers may thus first inhibit 
cell proliferation and ultimately produce metabolic 
synthetic lethality, as glucose levels decrease. Moreover, 
the rapid glucose processing in Met-treated cells has been 
suggested to result in the depletion of key glycolytic 
intermediates [51], effect that could be intensified by the 
combination with Prop. Indeed, it is important to note that 
all the observed effects of Met and Prop on mitochondrial-
dependent metabolism could be associated with a putative 
inhibition of mitochondrial superoxide production as 
these drugs both inhibit mitochondrial complex I and 
propranolol display antioxidant effects [19].
Progression of cancer is a dynamic process that also 
requires the gain of invasive and migratory capabilities. A 
proof-of principle epidemiological pilot study highlighted 
that β-blockers reduce distant metastasis in breast cancer 
patients [52]. Recent studies showed that these drugs 
could decrease the pro-migratory effect of β-adrenergic 
receptors [53] and inhibit cell scattering by enhancing cell-
cell adhesion [54] in breast cancer models. In the present 
study, we observed that the combination of Met + Prop 
altered breast cancer cell abilities to migrate and invade 
in vitro. Consistently, Met + Prop combination was highly 
efficient in preventing metastatic spreading in vivo, by 
diminishing the seeding capacity and the cell growth at the 
secondary tumor sites. This treatment feature is extremely 
important, as the main cause of mortality in patients with 
breast cancer is the development of metastasis and the 
scarcity of therapeutic options.
There is increasing evidence that metabolic 
plasticity is a major driver of cancer metastasis. While 
the aerobic glycolysis has long been thought to be linked 
to the metastatic potential of tumors, recent studies 
demonstrate that OXPHOS is indispensable for tumor 
migration and metastasis (extensively reviewed in [55]). 
Disseminating breast cancer cells indeed display increased 
levels of mitochondrial respiration [56]. The ability of 
Met + Prop combination to inhibit rapidly and efficiently 
the mitochondrial bioenergetics thus likely underlies the 
strong anti-metastatic properties of the treatment. Of note, 
this therapeutic strategy could especially be important to 
prevent breast cancer brain metastases, in which enhanced 
oxidative metabolism is associated with strongly increased 
tumor cell survival and proliferation [57]. 
Taking all together, our results indicate that the 
combination between Met and Prop is particularly 
effective in two different triple-negative, syngeneic 
breast cancer models, causing a significant metastasis-
free prolonged survival with a favorable toxicity profile. 
This strongly suggests the possibility of using these 
repositioned drugs combination for the treatment of triple-
negative metastatic breast cancer. As a matter of fact, it 
would be extremely interesting to test the benefits of such 
a combination when using as an adjuvant treatment after 
surgery in order to prevent metastasis development and/or 
recurrences or even as a perioperative therapy during the 
surgical resection of tumors.
MATERIALS AND METHODS
Cell culture
All cells were incubated at 37oC with 5% CO2. 4T1 
cells were kindly provided by Dr. N. Zwirner (IBYME-
CONICET). M-406 and M-234p derived-cells were 
obtained by disruption of tumors as described before [58]. 
These cells were cultured in RPMI supplemented with 
10% fetal calf serum (FCS), penicillin (10 μg/ml), and 
streptomycin (100 μg/ml). MCF7 and MDA-MB-231 were 
kindly provided by Dr. G. Gil (CIQUIBIC-CONICET) and 
were maintained in DMEM supplemented with 10% FCS, 
penicillin (10 μg/ml) and streptomycin (100 μg/ml). 
Proliferation
 For in vitro assessment of cell proliferation 
inhibition by Met (Metformin hydrochloride, Sigma-
Aldrich) and Prop (Propranolol hydrochloride; Sigma-
Table 2: Analysis of lungs collected from mice bearing M-406 breast tumors under the indicated 
treatments
Mice with metastasis
Treatment % nmet/ntot
Control 100 16/16
Metformin 84.21 16/19
Propranolol  72.22* 13/18
Metformin + Propranolol   58.33* 7/12
*Prop vs Control: P = 0.022448.
*M + P vs Control: P = 0.018521.
Significant differences obtained by Chi-square statistic test analysis are indicated. nmet; number of mice with metastasis. ntot; 
total number of mice.
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Aldrich) and their combination on breast cancer cells, 
5 × 103 cells/well were plated on 96-well culture plates. 
After attachment, different concentrations of Met and/
or Prop were added and cells were allowed to grow 
for 24 hours. The number of living cells was estimated 
indirectly by tetrazolium salts reduction method (WST-1, 
Sigma Aldrich) as described by the manufacturer. The 
amount of formazan dye formed directly correlates to 
the number of metabolically active cells in the culture. 
Proliferation was expressed as the percentage of control 
untreated samples. 
The concentration of drugs that decreased cell 
proliferation by 50% (IC50) as compared to controls was 
calculated using experimental data with the ED50plus 
v1.0 program. To determine IC50 values on metronomic 
treatment, cells were plated in 24-well plates (103 cells/well) 
and allowed to attach. Cells were treated with Met or 
Prop continuously for 144 h in 0.1 ml of medium, adding 
fresh medium and drug every 24 h to mimic continuous 
metronomic treatment [59].
Impedance measurements of cell proliferation
Impedance-based real time detection of 
cell proliferation and viability was done using the 
xCELLingence technology of the RTCA SP system 
(ACEA Biosciences, Ozyme, France). 4T1 or MDA-
MB-231 breast cancer cells were seeded in E-Plate 96-well 
plates (5 × 103 cells/well) for 24 hours, and were treated 
with metformin 1–7.5 mM alone, propranolol 10 µM 
alone, or their combinations. At cell seeding and after drug 
administration impedance changes were monitored every 
5 minutes for 8 hours, and every 15 minutes for the rest 
of the experiment. Cell index (CI) values derived from the 
recorded impedance data, were normalized (NCI) using 
the RTCA Software 2.0 (ACEA Biosciences, Ozyme, 
France). Data of each single well were normalized to 
the first measurement after starting treatment using the 
equation NCI(time) = CItime/CInml time. 
Clonogenic efficiency 
Cells (500/well) were plated on 6-well plates. After 
attachment, they were cultured in the presence of Met 
(5 mM) and/or Prop (5 µM) during 8 days. Photos of the 
clones were taken at different times and their size was 
estimated by measuring colonies diameters with the Image 
J software. After fixing the cells with formalin (4% PBS-
buffered p-formaldehyde (Anedra)), colonies were stained 
with Giemsa to allow quantification. 
Apoptosis
After 24 hours of treatment with Met (5 mM) and/or 
Prop (5 µM), cells were collected, washed and stained with 
Annexin V-FITC (AP-Biotech) and Propidium Iiodide. 
Apoptotic rates were determined by flow cytometry.
Migration
A wound was performed with a yellow tip on 
subconfluent 4T1 or MDA-MB-231 cells (time 0). 
Cellular motility was estimated by measuring closure 
of the initial wound. Photos were taken at the indicated 
times and quantification of healing was performed using 
the Image J software. Areas under the curve values were 
determined as described [60]. To analyze cellular motility 
in non-proliferative conditions, cells were put on media 
supplemented with 0,1% FCS overnight, and maintained 
under this condition during the whole assay.
Invasion assay
In vitro cell invasion assays were performed in 10-mm 
diameter and 8 μm pore polycarbonate filter transwell 
plates (Millipore). Membranes were pre-coated with 
20 μg of matrigel (BD Biosciences) on the upper surface, 
which formed a reconstituted basement membrane at 
37°C. Cells (8 × 105 in 100 μL media + 1% FBS) were 
seeded onto the upper well of the chamber, and the lower 
well was filled to the top (600 μL) with media + 10% 
FCS as chemoattractant. Treatments (Met 5 mM and/or 
Prop 5 µM) were added to both upper and lower media. 
After 24 hours incubation, cells were fixed in formalin 
and stained with Giemsa. Non-migrating cells were then 
carefully removed from the upper surface of the transwell 
with a wet cotton swab. Cells that had migrated to or 
invaded the bottom surface of the filter were counted. Six 
evenly spaced fields of cells were counted in each well 
using an inverted phase-contrast microscope.
Real-time analysis of energetic metabolism
Multiparameter metabolic analysis of intact cells 
was performed in the Seahorse XF24 extracellular flux 
analyzer (Seahorse Bioscience, Billerica, MA, USA). 
4T1 cells were seeded in XF24 V7 24-well plates 
(1.5 × 104 cells/well) and incubated overnight at 37°C in 
5 % CO2. Cells were then treated with metformin and/or 
propranolol for 4, 24 or 48 hours prior to the assay. To 
measure the glycolytic activity, cell culture medium was 
replaced for 1 h with minimal DMEM (0 mM glucose) 
supplemented with 2 mM glutamine and 1 mM sodium 
pyruvate, pH 7.4. Extracellular acidification rate (ECAR) 
was measured after sequential injections of glucose 
(10 mM), of the ATP synthase inhibitor oligomycin 
(1 µM), and of the glycolysis inhibitor 2-deoxyglucose 
(100 mM). To measure the mitochondrial activity, the 
same assay medium was used and supplemented with 
10 mM glucose. Oxygen consumption rate (OCR) was 
analyzed under these basal conditions and after sequential 
injections of oligomycin (1 µM), of the electron transport 
chain uncoupler FCCP (1 µM) and of specific inhibitors 
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of the mitochondrial respiratory chain antimycin 
A/rotenone (0.5 µM). To normalize OCR and ECAR data 
to cell number, 4T1 cells were simultaneously seeded 
and treated in a second multi-well plate. Cells were fixed 
with glutaraldehyde 1%, stained with violet crystal 0.1% 
(in methanol 20%), which was solubilized in DMSO to be 
analyzed with a microplate spectrophotometer.
Animal experiments
Six to eight-week-old inbred BALB/c and CBi 
female mice were obtained from our breeding facilities. 
Animals were fed with commercial chow and water 
ad libitum and maintained in a 12 h light/dark cycle. 
The animals were treated in accordance to the Canadian 
Council on Animal Care guidelines. Tumor bearing 
mice were euthanized by CO2 exposure. CBi mice were 
described before [58].
To carry out 4T1 primary breast cancer 
tumorigenesis analysis, 5 × 103 viable cells were 
resuspended in PBS (100 μl) and injected orthotopically 
into the fourth right mammary gland of the recipient 
mouse. For M-406 tumorigenesis, a tumor fragment of 
around 1 mm3 was orthotopically implanted in the fat pad, 
in the right mammary flank. Three days later, animals 
(N = 5–8/group) were distributed and treated as follows: 
Control: regular drinking water; Met: Met in drinking 
water (400 mg/kg BW/day); Prop: Prop in drinking water 
(7 mg/kg BW/day); Met × Prop: Met + Prop treatments 
combined. Primary tumor growth was analyzed by 
measuring tumor length (a) and width (b) with a caliper, 
and by calculating tumor volume (V) with the formula 
V = 0.4ab2. Fitting to exponential growth and tumor 
volume doubling times were calculated with the Prism 
6 software. Metastatic dissemination of tumor cells was 
quantified de visu after sacrificing the mice and at the same 
time tumors were extracted, fixed in 4% formaldehyde, 
and embedded in paraffin for hematoxylin/eosin staining. 
To highlight metastatic nodes, lungs were stained as 
described later on.
To carry out direct lung colonization assays, either 
5 × 104 4T1 cells or 2 × 105 M-406 cells were resuspended 
in 100 μl PBS and injected into the lateral tail vein. After 
2 wk, mice were euthanized, the chest cavity was exposed 
through a midline chest incision, the trachea cannulated 
with a 20-gauge needle, and lungs slowly inflated using 
1 ml of India ink (Pelikan, 1:16 dilution in PBS). Lungs 
were then extracted, immersed in Fekete’s solution 
(100 ml 70% ethanol (Cicarelli), 10 ml 4% formaldehyde 
(Anedra), and 5 ml 100% glacial acetic acid (Cicarelli)) to 
destain and metastatic nodules counted de visu. 
Immunostaining techniques 
Tissues were extracted, fixed in 4% paraformaldehyde 
(Anedra), cut into 5- to 6-µm- thick sections, and stained 
with H&E. For immunohistochemical staining, paraffin-
embedded sections were incubated with rabbit polyclonal 
antibody to Ki67 (Leica Biosystems, 1:50 dilution). After 
overnight incubation, tissue slides were rinsed with PBS, 
incubated for 1 hour at room temperature with Vectastain 
Elite ABC kit (Vector Laboratories, USA), developed with 
3,3´-diaminobenzidine (Sigma) and counterstained with 
hematoxilin. Quantification was done in a blind fashion 
by counting positive cells in 10 fields (400X). Apoptotic 
cells were detected with the TUNEL-based In Situ Cell 
Detection Kit (In situ cell death fluorescein, Sigma): 
Sections were deparaffinized, hydrated, and digested with 
proteinase K (Dako) for 30 min at 37°C and then subjected 
to the TUNEL reaction according to the manufacturer’s 
instructions; TUNEL-positive cells were visually scored 
with a standard immunofluorescence microscope (CTR600, 
Leica) and counted blindly in 8 fields (400X) chosen at 
random.
Statistics
Data obtained in lab experiments were analyzed 
using ANOVA and Tukey-Kramer Multiple Comparison 
tests, Kruskal-Wallis and Dunn’s post-test, and Log-
rank test were used to examine the differences between 
groups with GraphPad Prism version 3.0 (GraphPad 
Software, San Diego, CA). Unless otherwise indicated, 
results are expressed as mean ± sem of three independent 
experiments. P values lower than 0.05 were considered 
statistically significant.
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